bioMerieux (EYWN) Income Statement
bioMerieux Income Statement
Last quarter (Q2 2026), bioMerieux's total revenue was $1.96B, an increase of 3.30% from the same quarter last year. In Q2, bioMerieux's net income was $226.10M. See bioMerieux’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 4.07B | $ 3.98B | $ 3.67B | $ 3.59B | $ 3.38B | |
| $ 2.14B | $ 2.22B | $ 2.06B | $ 1.96B | $ 1.97B | |
| $ 1.58B | $ 1.63B | $ 1.62B | $ 1.40B | $ 1.20B | |
| Depreciation and Amortization | $ 438.40M | $ 302.20M | $ 259.40M | $ 257.60M | $ 220.40M |
| $ 999.60M | $ 897.50M | $ 701.30M | $ 811.90M | $ 977.80M | |
| $ 561.20M | $ 588.80M | $ 439.10M | $ 559.80M | $ 768.00M | |
| $ -35.70M | $ -9.50M | $ -1.60M | $ 20.70M | $ -9.80M | |
| $ 525.50M | $ 579.30M | $ 437.50M | $ 550.20M | $ 748.30M | |
| $ 397.50M | $ 432.20M | $ 357.60M | $ 452.40M | $ 601.10M | |
| Per Share Metrics | |||||
| Basic EPS | $ 3.37 | $ 3.67 | $ 3.03 | $ 3.84 | $ 5.08 |
| Diluted EPS | $ 3.34 | $ 3.64 | $ 3.01 | $ 3.82 | $ 5.06 |
| Weighted Average Shares Outstanding | 117.95M | 117.77M | 118.05M | 117.95M | 118.27M |
| Weighted Average Shares Outstanding (Diluted) | 119.01M | 118.74M | 118.80M | 118.44M | 118.89M |
Currency in EUR
